M&A Deal Summary |
|
|---|---|
| Date | 2006-11-21 |
| Target | ZAO ZiO-Zdorovie |
| Sector | Life Science |
| Buyer(s) | Allergan |
| Deal Type | Add-on Acquisition |
| Deal Value | 47M EUR |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1956 |
| Sector | Life Science |
| Employees | 31,200 |
| Revenue | 15.8B USD (2018) |
Allergan is an integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company was originally established in 1956 and is based in Parsippany, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 38 |
| Sector: Life Science M&A | 2 of 23 |
| Type: Add-on Acquisition M&A Deals | 5 of 31 |
| Country: Russia M&A | 1 of 1 |
| Year: 2006 M&A | 3 of 3 |
| Size (of disclosed) | 23 of 25 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2006-11-06 |
Andrx
Davie, Florida, United States Andrx Corporation is engaged in the formulation and commercialization of oral controlled-release pharmaceuticals utilizing its proprietary drug delivery technologies. In its ANDA program, Andrx is developing bio-equivalent or generic versions of selected high sales volume controlled-release brand name pharmaceuticals. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2009-06-17 |
Arrow Group
Horsholm, Denmark Founded in 2000, Arrow Group is a global generic pharmaceutical company. With commercial operations in over 20 countries, Arrow's geographic reach comprises a mix of established, growing and emerging markets worldwide. The company operates as Arrow Generics in the United Kingdom, as Cobalt Pharmaceuticals in the U.S. and Canada and as Arrow Generiques in France. Arrow also manages strategically located production facilities in Brazil, Canada and Malta, and employs 250 at its Australia-based R&D facility. |
Buy | $1.8B |
